Loading...

Cangrelor increases the magnitude of platelet inhibition and reduces interindividual variability in clopidogrel-pretreated subjects

BACKGROUND: Inadequate platelet inhibition despite aspirin and clopidogrel therapy during and after a percutaneous coronary intervention is associated with an impaired clinical outcome. Cangrelor, a direct and reversible P2Y(12) inhibitor that is currently in development, has the potential to achiev...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Main Authors: Bouman, H.J., van Werkum, J.W., Hackeng, C.M., Clappers, N., ten Berg, J.M.
Format: Artigo
Sprog:Inglês
Udgivet: Bohn Stafleu van Loghum 2009
Fag:
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC2688017/
https://ncbi.nlm.nih.gov/pubmed/19484155
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!